Working… Menu

The LD Lync Study - Natural History Study of Genetic Lipodystrophy Syndromes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03087253
Recruitment Status : Recruiting
First Posted : March 22, 2017
Last Update Posted : April 2, 2019
Information provided by (Responsible Party):
Elif Oral, University of Michigan

Brief Summary:

Genetic lipodystrophy syndromes are extremely rare, orphan diseases with overall estimated prevalence of less than 2,000 in the United States. These rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications diabetes, dyslipidemia and hepatic steatosis. Due to these metabolic problems, atherosclerotic vascular disease, recurrent episodes of acute pancreatitis, cirrhosis and other morbidities complicate the lives of these patients.

In the last few years, several genes for CGL (AGPAT2, BSCL2, CAV1 and PTRF); FPL (LMNA, PPARG, AKT2, CIDEC, LIPE, PLIN1, PCYT1A and ADRA2A); MAD (LMNA and ZMPSTE24); APS (LMNA); autoinflammatory (PSMB8); NPS (FBN1, CAV1); SHORT syndrome (PIK3R1); and MDP syndrome (POLD1) have been identified. However, there is paucity of information about the natural history of these rare syndromes, especially genotype-specific causes of morbidity and mortality.

To overcome the problems outlined above, this multicenter, collaborative, prospective, observational natural history cohort study will be conducted on approximately 500 patients with genetic lipodystrophy syndromes. Patients will be assessed on a yearly basis for approximately 4 years to collect robust clinical, metabolic, morbidity and mortality data. Medical history and patient questionnaires will be completed on a yearly basis by patients registered in the study. Clinical data such as vitals, laboratory results and anthropometric measurements will also be collected from patients' medical records if available.

Condition or disease
Lipodystrophy (Genetic or Acquired, Non HIV)

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 4 Years
Official Title: Prospective Multicenter Natural History Study of Genetic Lipodystrophy Syndromes to Determine Prevalence, Incidence and Predictors of Diabetes and Severe Hypertriglyceridemia, and Their Complications
Actual Study Start Date : February 27, 2018
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Triglycerides

Primary Outcome Measures :
  1. Prevalence of diabetes mellitus [ Time Frame: 4 years ]
    Number of subjects with diabetes mellitus or who develop diabetes mellitus

Secondary Outcome Measures :
  1. Prevalence of severe hypertriglyceridemia [ Time Frame: 4 years ]
    Number of subjects with severe hypertriglyceridemia (greater than 500 md/dL) or who develop severe hypertriglyceridemia

  2. Incidence of severe morbidities and causes of mortality [ Time Frame: 4 years ]
    Incidence of severe morbidities (acute pancreatitis, congestive heart failure, cirrhosis, liver failure) and causes of mortality in subjects

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with a clinical diagnosis of genetic lipodystrophy

Inclusion Criteria:

  • Clinical diagnosis of genetic lipodystrophy Supportive data: 1) Presence of biallelic known disease-causing variants in the genes for autosomal recessive lipodystrophy syndromes; 2) Presence of a known (or de novo loss of function) disease-causing variant in the genes for autosomal dominant lipodystrophy syndromes.

Exclusion Criteria:

  • HIV-infected patients with lipodystrophy
  • Drug-induced lipodystrophy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03087253

Layout table for location contacts
Contact: Adam Neidert, M.S. 734-615-0539
Contact: Elif Oral, M.D. 734-615-7271

Layout table for location information
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48105
Contact: Adam H Neidert, MS    734-615-0539   
Contact: Elif A Oral, MD    734-615-7271   
Principal Investigator: Elif A Oral, MD         
Sub-Investigator: Nevin N Ajluni, MD         
Sub-Investigator: Corey Lager, MD         
Sponsors and Collaborators
University of Michigan
Layout table for investigator information
Principal Investigator: Elif A Oral, MD Associate Professor of Medicine

Additional Information:

Layout table for additonal information
Responsible Party: Elif Oral, Associate Professor of Medicine, University of Michigan Identifier: NCT03087253     History of Changes
Other Study ID Numbers: HUM00127427
First Posted: March 22, 2017    Key Record Dates
Last Update Posted: April 2, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Metabolic
Skin Diseases
Lipid Metabolism Disorders
Metabolic Diseases